Nonapeptide-1
Nonapeptide-1 (Melanostatine-5) is an MSH antagonist peptide that competes for MC1R receptor binding to inhibit melanin synthesis, used in skin brightening and pigmentation correction products.
Nonapeptide-1 (also known as Melanostatine-5) is a synthetic nine-amino-acid peptide that acts as a competitive antagonist of alpha-melanocyte-stimulating hormone (alpha-MSH) at the melanocortin-1 receptor (MC1R). By blocking alpha-MSH from binding MC1R on melanocytes, nonapeptide-1 inhibits the signaling cascade that triggers melanin production, making it a targeted approach to skin brightening and hyperpigmentation correction without cytotoxic effects on melanocytes.
Overview
Melanin production in human skin is regulated by the alpha-MSH/MC1R signaling axis. When UV radiation damages keratinocytes, they release alpha-MSH, which binds MC1R on neighboring melanocytes and triggers an intracellular cascade through cAMP, CREB, and MITF that upregulates melanogenic enzymes including tyrosinase, TRP-1, and TRP-2. This protective response produces melanin pigment, but its dysregulation leads to hyperpigmentation disorders including melasma, post-inflammatory hyperpigmentation, and solar lentigines.
Nonapeptide-1 was designed to intercept this pathway at the receptor level. Its amino acid sequence mimics the MC1R-binding domain of alpha-MSH but lacks the ability to activate the receptor's signaling cascade. By occupying MC1R without triggering downstream signaling, nonapeptide-1 competitively blocks alpha-MSH from initiating melanogenesis.
Unlike hydroquinone (which inhibits tyrosinase and can damage melanocytes) or retinoids (which accelerate epidermal turnover), nonapeptide-1 works upstream of melanin synthesis at the receptor signaling level. This approach preserves melanocyte viability while reducing melanin output, offering a more physiologically targeted method of skin brightening.
Mechanism of Action
MC1R Competitive Antagonism
Nonapeptide-1 binds the extracellular domain of MC1R with affinity comparable to alpha-MSH but functions as a silent antagonist -- it occupies the binding site without inducing the conformational change necessary for G-protein coupling. This blocks alpha-MSH-stimulated adenylyl cyclase activation, preventing the rise in intracellular cAMP that initiates the melanogenic cascade.
Downstream Pathway Inhibition
By preventing cAMP elevation, nonapeptide-1 indirectly suppresses:
- CREB phosphorylation: The transcription factor CREB normally activates MITF gene expression in response to alpha-MSH signaling
- MITF expression: Microphthalmia-associated transcription factor is the master regulator of melanocyte differentiation and melanogenic enzyme expression
- Tyrosinase transcription: The rate-limiting enzyme in melanin biosynthesis is transcriptionally controlled by MITF
- TRP-1 and TRP-2: Additional melanogenic enzymes under MITF control
Melanin Reduction Without Melanocyte Toxicity
A critical advantage of nonapeptide-1 over cytotoxic depigmenting agents is that it does not damage or destroy melanocytes. The cells remain viable and capable of producing melanin if the antagonist is removed. This reversibility reduces the risk of permanent depigmentation (leukoderma) associated with agents like monobenzyl ether of hydroquinone. Melanocyte preservation also means that the skin retains its capacity for photoprotective melanin production in response to UV exposure when treatment is discontinued.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
In Vitro Melanogenesis Inhibition
Studies using B16F10 melanoma cells and primary human melanocyte cultures have demonstrated that nonapeptide-1 reduces melanin content by 30-50% at concentrations of 10-100 micromolar. The inhibition is dose-dependent and reversible upon peptide removal. Cell viability assays confirm that nonapeptide-1 does not reduce melanocyte numbers at effective concentrations, confirming its non-cytotoxic mechanism.
Clinical Efficacy in Brightening Formulations
Nonapeptide-1 is incorporated into commercial skin brightening products at concentrations typically ranging from 0.001-0.01%. Clinical evaluations of formulations containing nonapeptide-1 report visible reduction in skin pigmentation and improvement in skin luminosity after 4-8 weeks of twice-daily application. Colorimetric measurements (L* values) show statistically significant brightening compared to vehicle control.
Comparison with Other Brightening Peptides
In comparative studies, nonapeptide-1 demonstrates a distinct mechanism from other peptide-based brightening agents:
- Oligopeptide-68 (B-White): Inhibits tyrosinase activity and MITF expression directly
- sh-Decapeptide-10 (Lumixyl): Regulates tyrosinase function through a non-competitive mechanism
- Nonapeptide-1 works upstream of both, blocking the receptor signal that triggers the entire melanogenic cascade
These complementary mechanisms suggest potential synergy when nonapeptide-1 is combined with downstream melanogenesis inhibitors.
Combination Approaches
Nonapeptide-1 has been studied in combination with niacinamide (which blocks melanosome transfer to keratinocytes) and vitamin C derivatives (which reduce oxidized melanin). The combination targets melanin production at multiple steps: receptor signaling (nonapeptide-1), enzymatic synthesis (vitamin C), and cellular distribution (niacinamide), providing more comprehensive brightening than any single agent.
Safety Profile
Nonapeptide-1 has a favorable safety profile consistent with topical cosmetic peptides. As a competitive antagonist that does not damage melanocytes, it avoids the ochronosis risk of hydroquinone and the irritation potential of retinoids. No significant adverse effects have been reported in clinical evaluations of nonapeptide-1-containing formulations. The peptide does not penetrate to systemic circulation at topical concentrations used in cosmetics. It is non-irritating, non-sensitizing, and compatible with most cosmetic formulation ingredients. Because it reduces but does not eliminate melanin production, it does not cause the patchy depigmentation seen with more aggressive treatments. Sunscreen use is recommended during brightening treatment to prevent UV-stimulated melanogenesis from counteracting peptide effects.
Pharmacokinetic Profile
- Half-life
- Not established (topical use)
Quick Start
- Route
- Topical
Molecular Structure
- Formula
- C50H73N13O15
- Weight
- 1206.5 Da
- CAS
- 158563-45-2
- PubChem CID
- 10418849
- Exact Mass
- 1205.6532 Da
- LogP
- 2.3
- TPSA
- 416 Ų
- H-Bond Donors
- 12
- H-Bond Acceptors
- 13
- Rotatable Bonds
- 33
- Complexity
- 2280
Identifiers (SMILES, InChI)
InChI=1S/C61H87N15O9S/c1-37(2)51(52(64)77)74-58(83)50-26-16-31-76(50)60(85)45(23-12-13-28-62)70-55(80)46(33-38-17-6-4-7-18-38)71-56(81)48(35-40-36-68-43-22-11-10-21-41(40)43)72-53(78)44(24-14-29-67-61(65)66)69-54(79)47(34-39-19-8-5-9-20-39)73-57(82)49-25-15-30-75(49)59(84)42(63)27-32-86-3/h4-11,17-22,36-37,42,44-51,68H,12-16,23-35,62-63H2,1-3H3,(H2,64,77)(H,69,79)(H,70,80)(H,71,81)(H,72,78)(H,73,82)(H,74,83)(H4,65,66,67)/t42-,44-,45-,46-,47+,48+,49-,50-,51-/m0/s1
KNFLNGRLKALWRF-LDXSYGEZSA-NResearch Protocols
topical
Safety Profile Nonapeptide-1 has a favorable safety profile consistent with topical cosmetic peptides. The peptide does not penetrate to systemic circulation at topical concentrations used in cosmetics.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | See literature | Daily | 4-8 weeks(Route: Topical) |
Interactions
Peptide Interactions
In comparative studies, nonapeptide-1 demonstrates a distinct mechanism from other peptide-based brightening agents: - Oligopeptide-68 (B-White): Inhibits tyrosinase activity and MITF expression directly - sh-Decapeptide-10 (Lumixyl): Regulates tyrosinase function through a non-competitive mechan...
Quality Indicators
What to look for
- Well-established safety profile
Frequently Asked Questions
References (7)
- [5]
- [9]Pillaiyar et al - Melanocortin receptor ligands for skin pigmentation modulation: recent advances J. Med. Chem. (2023)
- [10]Heriniaina et al - Peptide-based approaches to melanogenesis inhibition: receptors, enzymes, and transcription factors Molecules (2022)
- [11]Boo - Melanogenesis inhibitory peptides: current status and future prospects Int. J. Mol. Sci. (2022)
- [6]
- [7]
- [8]
Nociceptin/Orphanin FQ
Nociceptin (Orphanin FQ, N/OFQ) is a 17-amino-acid neuropeptide that signals through the NOP receptor (ORL-1). Structurally related to dynorphin but functionally distinct from classical opioids, it modulates pain, stress, anxiety, and addiction through complex, often anti-opioid mechanisms.
NT-3
Neurotrophin-3 (NT-3) is a member of the neurotrophin family that signals primarily through the TrkC receptor to promote survival and regeneration of proprioceptive neurons, spinal cord axons, and cochlear neurons, with emerging applications in spinal cord injury and hearing loss research.